iTeos Therapeutics Logo
US46565G1040
A2P90X
ITOS

iTeos Therapeutics

Loading quotes...

Forecast

The analysts' average price target is €16.54 (+90.33%). The median is €10.91 (+25.55%).

Buy
  3
Hold
  5
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • iTeos Therapeutics acquired by Concentra and delisted from Nasdaq

    iTeos Therapeutics became a wholly owned subsidiary of Concentra Biosciences through a merger and its shares were delisted from the Nasdaq; shareholders received USD 10.047 in cash plus a contingent value right (CVR). All merger conditions were met, about 72.17% of outstanding shares were tendered, the board of directors of iTeos resigned and leadership positions were filled by representatives of Concentra Merger Sub VIII, Inc. Leerink Partners cut its price target for iTeos in light of the takeover; the company intends to terminate its SEC registration. » More on de.investing.com

Financials

In the last quarter, iTeos Therapeutics had revenue of €0 and net profit of -€66.8M
(EUR) June 2025
YoY
Revenue 0 -
Gross profit 0 -
Net profit -66.8M -
EBITDA -56.15M -

Fundamentals

Metric Value
Market capitalization
€407.83M
Number of shares
44.21M
52-week high/low
€16.02 - €4.36
Dividends No
Beta
1.49
P/E ratio
-3.06
PEG ratio
0.06
P/B ratio
0.70
P/S ratio
12.82

Company profile

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Name
iTeos Therapeutics
CEO
Michel Detheux
Headquarters Watertown, ma
USA
Website
Sector
Health Care
Industry
Pharmaceuticals
IPO
07/24/2020
Employees 173

Ticker symbols

Exchange Symbol
NASDAQ
ITOS
🍪

Parqet  uses cookies. Learn more